Nature neuroscienceOct 20, 2026

Disrupted cholesterol movement by ABCA1 may lead to nerve cell damage in Parkinson's disease

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 22, 2026

Abstract

ABCA1 expression is elevated in the substantia nigra of postmortem Parkinson's disease brains and a mouse model.

ABCA1 is identified as a critical regulator of cholesterol levels in Parkinson's disease.
Increased ABCA1 expression is associated with changes in nigral and striatal brain regions.
Astrocytic ABCA1 may cause excessive cholesterol loss from astrocytes, contributing to neuronal cholesterol buildup.
Cholesterol accumulation in neurons is linked to autophagy impairment and increased α-synuclein pathology.
Silencing Abca1 in astrocytes or dopaminergic neurons reduces neurodegeneration and improves behavior in mice.
Magnesium citrate is identified as an ABCA1 inhibitor, which may decrease neuronal loss in a Parkinson's disease mouse model.

Simplified

Although brain cholesterol dysregulation is implicated in Parkinson's disease (PD), targeting cholesterol synthesis has shown limited efficacy. Here we identify ATP-binding cassette transporter A1 (ABCA1) as a critical regulator of cholesterol homeostasis in PD. We show that ABCA1 expression is elevated in the substantia nigra of postmortem PD brains and in a PD mouse model, with regional analyses revealing preferential alterations in nigral and striatal circuits. Mechanistically, astrocytic ABCA1 drives excessive cholesterol efflux in mice, promoting neuronal cholesterol overload. In neurons, ABCA1 localizes to lysosomes, where it facilitates cholesterol import, leading to cholesterol accumulation, autophagy impairment and α-synuclein pathology. Genetic silencing of Abca1 in either astrocytes or dopaminergic neurons attenuates neurodegeneration and behavioral deficits in vivo. Furthermore, we identify magnesium citrate as an ABCA1 inhibitor and show that it reduces dopaminergic neuronal loss in a PD mouse model. Our findings identify an ABCA1-dependent cholesterol pathway underlying PD pathogenesis and support ABCA1 inhibition as a potential disease-modifying strategy.

Full Text

Full text is available at the source.

View Full Text ↗

Disrupted cholesterol movement by ABCA1 may lead to nerve cell damage in Parkinson's disease

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief